All In Biotech

Drug Trial Radar · NCT06660667

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

A Phase 1/2 Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR402663 in Participants With Neovascular Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Nov 21, 2024

Primary completion

May 18, 2027

Study completion Jun 30, 2031

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration. Participants will be enrolled in one of 2 parts: * In Part I (dose escalation), multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants * In Part II (dose expansion), participants will be randomized to receive one of two dose levels selected based on data from Part I. Participants, investigators and outcomes assessors will be masked to dose. After receiving one-time dose of SAR402663, participants will undergo regular assessments over 12 months. Following this, participants will enter an extended follow-up (EFU) phase for the assessment of safety and durability of clinical activity of SAR402663 through Year 5.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • SAR402663Biological

    Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection

  • DiluentDrug

    Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of ocular treatment emergent adverse event (TEAEs)Time frame: Day 1 to Week 52
  2. Incidence and severity of ocular treatment emergent serious adverse event (TESAEs)Time frame: Day 1 to Week 52
  3. Incidence and severity of non-ocular TEAEsTime frame: Day 1 to Week 52
  4. Incidence and severity of non-ocular TESAEsTime frame: Day 1 to Week 52
  5. Number of participants with any clinically significant changes in laboratory variablesTime frame: Day 1 to Week 52
  6. Number of participants with any clinically significant changes in vital signsTime frame: Day 1 to Week 52

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants - Phoenix- Site Number : 8400011

    Phoenix, Arizona

  • Retina Macula Institute of Arizona- Site Number : 8400028

    Scottsdale, Arizona

  • California Retina Consultants - Bakersfield- Site Number : 8400001

    Bakersfield, California

  • Retina-Vitreous Associates Medical Group - Beverly Hills- Site Number : 8400023

    Beverly Hills, California

  • Vitreo Retinal Associates - Gainesville- Site Number : 8400004

    Gainesville, Florida

  • Retina Vitreous Associates of Florida - St. Petersburg- Site Number : 8400002

    St. Petersburg, Florida

  • Southeast Retina Center- Site Number : 8400010

    Augusta, Georgia

  • University Retina - Lemont- Site Number : 8400005

    Lemont, Illinois

  • Cumberland Valley Retina Consultants - Hagerstown- Site Number : 8400003

    Hagerstown, Maryland

  • Retina Specialist- Site Number : 8400020

    Towson, Maryland

  • Ophthalmic Consultants of Boston - Boston- Site Number : 8400009

    Boston, Massachusetts

  • Sierra Eye Associates- Site Number : 8400021

    Reno, Nevada

  • North Carolina (Nc) Retina Associates - Wake Forest Office- Site Number : 8400033

    Wake Forest, North Carolina

  • Oregon Retina- Site Number : 8400017

    Eugene, Oregon

  • Mid Atlantic Retina- Site Number : 8400032

    Bethlehem, Pennsylvania

  • Charleston Neuroscience Institute - Ladson- Site Number : 8400016

    Ladson, South Carolina

  • Charles Retina Institution- Site Number : 8400018

    Germantown, Tennessee

  • Retina Research Institute of Texas- Site Number : 8400008

    Abilene, Texas

  • Austin Research Center for Retina- Site Number : 8400015

    Austin, Texas

  • Austin Clinical Research - Austin - Anderson Mill Road- Site Number : 8400007

    Austin, Texas

  • Texas Retina Associates - Dallas- Site Number : 8400006

    Dallas, Texas

  • Medical Center Ophthalmology Associates- Site Number : 8400030

    San Antonio, Texas

  • Retinal Consultants of Texas - San Antonio- Site Number : 8400012

    San Antonio, Texas

  • Retina Consultants of Texas - The Woodlands- Site Number : 8400019

    The Woodlands, Texas

  • Investigational Site Number : 8260027

    Liverpool, United Kingdom

  • Investigational Site Number : 8260024

    London, Westminster, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.